Dr. Hamlin on Future Combination Strategies in the MCL Landscape

Paul A. Hamlin, MD
Published: Wednesday, Sep 06, 2017



Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

This is likely where researchers are heading as a field, Hamlin explains. In MCL, the focus has really been in incorporating novel agents into treatment paradigms, as well as challenging whether or not autologous stem cell transplantation needs to be part of an induction regimen or whether or not the novel agents can give patients the same benefit in terms of disease control. Nevertheless, US and European investigators are looking at novel combinations, including a BCL-2 inhibitor plus a BCR inhibitor or PI3K inhibitor.

These are active areas of research, especially with incorporating these agents into a backbone of chemotherapy induction.
SELECTED
LANGUAGE


Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

This is likely where researchers are heading as a field, Hamlin explains. In MCL, the focus has really been in incorporating novel agents into treatment paradigms, as well as challenging whether or not autologous stem cell transplantation needs to be part of an induction regimen or whether or not the novel agents can give patients the same benefit in terms of disease control. Nevertheless, US and European investigators are looking at novel combinations, including a BCL-2 inhibitor plus a BCR inhibitor or PI3K inhibitor.

These are active areas of research, especially with incorporating these agents into a backbone of chemotherapy induction.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x